Xampla is collaborating with Britvic to develop vitamin microcapsules that may be mircopackaged in beverages without affecting the taste and the risk of degradation during transit and storage.
A microscopic droplet of vitamin oil wrapped in a plant-based material protects the vitamin, such as vitamin D, from ultra-violet light, pH imbalance, and pasteurization.
The vitamin microcapsules, according to Xampla, "increase the volume of effective vitamins without affecting the product's taste."
Any oil-based vitamin or flavor, including vitamins A, D, E, and K, can be packaged using this technology.
Simon Hombersley, CEO of Xampla, described their product as microcapsules that “offer an opportunity for big beverage brands to get the vitamins people need directly to them inside everyday products”.
He added that the vitamin microcapsule provides a much-needed, simple solution for brands to infuse vitamin D safely in clear bottles, as well as the potential to micropackage a whole range of other nutrients in the future.
Xampia is working with multi-nationals to bring this product to supermarket shelves.


US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold
Tesla Semi Rollout Begins at Nevada Factory
Fed Unveils Stablecoin Rules Under GENIUS Act
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering
France Keeps Top Health Alert as Officials Brace for Another Heatwave
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Asian Currencies Mixed as Dollar Holds Near Two-Month High
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes
RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity
Canadian Dollar Faces Pressure as Fed-BoC Policy Gap Widens
U.S. Issues Cuba Health Alert as Illnesses Rise
3 clinical-grade skincare creams you really shouldn’t buy online
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Solidigm Eyes $150 Billion IPO as SK Hynix Expands AI Storage Push 



